The Preliminary Results of 125I Interstitial Brachytherapy for Locally Recurrent Parotid Gland Cance

• 作 者: LeiZheng;JianguoZhang;JieZhang;TieliSong;MingweiHuang;GuangyanYu;
• 机 构: Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology,
• 出 处: 北京大学医学部放射肿瘤学系成立大会暨北京大学第二届国际放射肿瘤学术论坛
• 发表日期: 2012年期

　　Background: This study analyzed the treatment of recurrent parotid gland cancers with radioactive iodine (125I) seed implantation.Methods: Fifteen patients with recurrent previously irradiated parotid gland cancers were treated with postoperative 125I seed implantation between April 2004 and June 2009.Local control, survival rates and side effects were retrospectively reviewed.Results:The 3-and 5-year local control rates were 67% and 53.6%, and the overall survival rates were76.2% and 66.7%, respectively.Four House-Brackman grade Ⅳ patients recovered to grade Ⅱduring follow-up.Four patients (26.7%) developed grade Ⅳ skin ulceration.Two patients (13.3%)developed moderate fibrosis of the subcutaneous tissues, and two (13.3%) suffered hearing loss for1 year after brachytherapy.There were no severe late toxicities.Conclusions: This study showed improved local control and survival rates in patients who received 125I brachytherapy.These findings should be interpreted cautiously due to the small number of patients.